NCT06625398: An ongoing trial by Viridian Therapeutics, Inc.
This trial is ongoing. It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06625398 |
|---|---|
| Title | REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 27, 2024 |
| Completion date | April 1, 2026 |
| Required reporting date | April 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |